Brief: Dyadic Applied BioSolutions Expands Genetic Engineering Capabilities Through CRISPR/Cas9 Commercial License with ERS Genomics
10/11/2025 12:28
Nov 10 (Reuters) - Dyadic International Inc DYAI.O: DYADIC APPLIED BIOSOLUTIONS: EXPANDS GENETIC ENGINEERING CAPABILITIES THROUGH CRISPR/CAS9 COMMERCIAL LICENSE WITH ERS GENOMICS DYADIC APPLIED BIOSOLUTIONS: FINANCIAL DETAILS OF AGREEMENT WERE NOT DISCLOSED Source text: ID:nGNE19flXv Further company coverage: DYAI.O ((reuters.briefs@thomsonreuters.com;))
Recent news on Dyadic International
See all newsDyadic International Inc reports results for the quarter ended June 30 - Earnings Summary
Dyadic International Inc expected to post a loss of 4 cents a share - Earnings Preview
Brief: Dyadic International - Develops C1 Cell Lines And Manufactures Bundibugyo Ebolavirus Antigens Within 15 Days
Brief: Dyadic Announces Continued Listing On The Nasdaq Capital Market
Brief: Dyadic And Scripps Research Collaborate On Rapid-Response Hantavirus Antibody And Vaccine Development